- Home
- CELC vs HCI Comparison
CELC vs HCI Comparison
Compare CELC & HCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELC
- HCI
- Stock Information
- Founded
- CELC 2011
- HCI 2006
- Country
- CELC United States
- HCI United States
- Employees
- CELC N/A
- HCI N/A
- Industry
- CELC Medical Specialities
- HCI Property-Casualty Insurers
- Sector
- CELC Health Care
- HCI Finance
- Exchange
- CELC Nasdaq
- HCI Nasdaq
- Market Cap
- CELC 2.3B
- HCI 2.5B
- IPO Year
- CELC 2017
- HCI N/A
- Fundamental
- Price
- CELC $50.51
- HCI $193.79
- Analyst Decision
- CELC Strong Buy
- HCI Strong Buy
- Analyst Count
- CELC 6
- HCI 4
- Target Price
- CELC $63.00
- HCI $181.25
- AVG Volume (30 Days)
- CELC 1.0M
- HCI 173.6K
- Earning Date
- CELC 11-13-2025
- HCI 11-06-2025
- Dividend Yield
- CELC N/A
- HCI 0.83%
- EPS Growth
- CELC N/A
- HCI N/A
- EPS
- CELC N/A
- HCI 11.47
- Revenue
- CELC N/A
- HCI $775,545,000.00
- Revenue This Year
- CELC N/A
- HCI $19.75
- Revenue Next Year
- CELC N/A
- HCI $8.24
- P/E Ratio
- CELC N/A
- HCI $16.86
- Revenue Growth
- CELC N/A
- HCI 9.67
- 52 Week Low
- CELC $7.58
- HCI $91.06
- 52 Week High
- CELC $63.06
- HCI $194.19
- Technical
- Relative Strength Index (RSI)
- CELC 49.45
- HCI 68.22
- Support Level
- CELC $44.42
- HCI $184.23
- Resistance Level
- CELC $52.76
- HCI $193.30
- Average True Range (ATR)
- CELC 3.10
- HCI 5.63
- MACD
- CELC -1.11
- HCI 0.09
- Stochastic Oscillator
- CELC 51.39
- HCI 97.88
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
About HCI HCI Group Inc.
HCI Group Inc is engaged in the property and casualty insurance business through two Florida domiciled insurance companies, Homeowners Choice Property & Casualty Insurance Company (HCPCI) and TypTap Insurance Company (TypTap). Both HCPCI and TypTap are authorized to underwrite various homeowners' property and casualty insurance products and allied lines business in the state of Florida and other states. The operating segments of the group are insurance operations, TypTap Group, reciprocal exchange operations, real estate operations, and corporate and other. It derives key revenue from the HCPCI Insurance operation segment.